Endo Inc.
Endo Inc., a prominent player in the pharmaceutical and medical device industry, is headquartered in the United States. Founded in 1997, the company has established itself as a leader in pain management, urology, and other therapeutic areas, with a strong operational presence across North America and Europe. Endo Inc. is renowned for its innovative products, including advanced pain relief medications and minimally invasive surgical devices, which are designed to improve patient outcomes. The company’s commitment to quality and efficacy has earned it a significant market position, marked by notable achievements in research and development. With a focus on addressing unmet medical needs, Endo Inc. continues to drive advancements in healthcare, making a meaningful impact on patients' lives.
DitchCarbon Score
How does Endo Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Endo Inc.'s score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Endo Inc.'s reported carbon emissions
In 2024, Endo Inc. reported total carbon emissions of approximately 64,570,000 kg CO2e, comprising about 14,557,000 kg CO2e from Scope 1 and about 49,401,000 kg CO2e from Scope 2 emissions. This marks a slight increase in emissions compared to 2023, where the total was approximately 59,785,000 kg CO2e, with Scope 1 emissions at about 13,435,000 kg CO2e and Scope 2 emissions at about 45,570,000 kg CO2e. Over the past few years, Endo's emissions have fluctuated, with 2022 emissions recorded at approximately 48,298,000 kg CO2e (12,718,000 kg CO2e from Scope 1 and 36,208,000 kg CO2e from Scope 2) and 2021 emissions at about 60,690,000 kg CO2e (16,872,000 kg CO2e from Scope 1 and 43,967,000 kg CO2e from Scope 2). The highest emissions were noted in 2019, with a total of approximately 64,700,000 kg CO2e. Endo Inc. has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of Scope 3 emissions data indicates a potential area for future reporting and improvement. Overall, while Endo Inc. has made strides in tracking its emissions, further commitments and reduction strategies may be necessary to align with industry standards and climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 27,475,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Endo Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
